|
|
1.
|
NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC->paclitaxel (P) plus gemcitabine (G) with DD AC->P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. MedStar authors:
Year: 2012
Citation: - Journal of Clinical Oncology. 30(18_suppl):LBA1000, 2012 Jun 20
Institution: - Medstar Franklin Square Medical Center
Medline publication type:
All authors: - Atkins JN, Azar CA, Biggs DD, Brufsky A, Costantino JP, Donnellan PP, Fehrenbacher L, Geyer CE, Levine EA, Mamounas EP, Paik S, Perez EA, Polikoff J, Provencher L, Rastogi P, Robidoux A, Tang G, Wolmark N, Zapas JL
|
|
|
2.
|
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2. MedStar authors:
- Swain, Sandra M
- Zapas, John L
Year: 2017
Citation: - Journal of Clinical Oncology. 35(35):3942-3948, 2017 Dec 10
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Atkins JN, Biggs DD, Brufsky AM, Cecchini RS, Fehrenbacher L, Flynn PJ, Ganz PA, Geyer CE Jr, Gross HM, Jeong JH, Mamounas EP, Polikoff J, Rastogi P, Romond EH, Seay TE, Swain SM, Wade JL 3rd, Wahl TA, Wolmark N, Zapas JL
|
